A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs MABp1 (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors XBiotech
- 13 Oct 2017 This study has been completed in Poland as per European Clinical Trials Database.
- 10 Oct 2017 This trial has been completed in Hungary (End Date:2017-07-07).
- 26 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History